Oral bisphosphonate-related osteonecrosis of the jaws: a case report
Osteonecrose dos maxilares relacionada ao uso de bisfosfonatos orais: relato de caso
Ribeiro, Renato da Costa; Vitorino, Nauber de Souza; Freitas, Paulo Henrique Luiz de; Souza, Rodrigo Calado Nunes e
Rev. odontol. UNESP, vol.40, n5, p.264-267, 2011
Abstract
Bisphosphonates are a class of drugs characterized by being potent inhibitors of osteoclast-driven bone resorption, and are currently used for treatment of various conditions such as osteoporosis and metastatic lesions in bone. There has been an increase in reports of a serious side effect of these drugs, the bisphosphonate-related osteonecrosis of the jaws (BRONJ). We report on the case of a female patient who had been in use of oral alendronate for over 10 years due to osteoporosis. She presented to our outpatient clinics with painful exposure of bone intra-orally (hard palate and mandibular body). In this work, the pertinent literature is reviewed and the management of the condition is discussed
Keywords
Osteonecrosis, jaws, osteoporosis
Resumo
Os bisfosfonatos são uma classe de medicamentos caracterizados como potentes inibidores da reabsorção óssea conduzida por osteoclastos e têm sido empregados para o tratamento de diversas entidades patológicas que atingem o tecido ósseo, como osteoporose e metástases ósseas de tumores malignos. Porém, vem aumentando o número de publicações em relação a um efeito colateral destas drogas: a osteonecrose dos maxilares relacionada aos bisfosfonatos (OMARB). Este trabalho relata o caso de uma paciente que fazia uso de alendronato por via oral, por um período de aproximadamente dez anos, para tratamento de osteoporose. Na evolução do caso, verificou-se exposição óssea em região de palato duro e corpo de mandíbula, associada a quadro de dor. Foi conduzida uma revisão da literatura pertinente e o manejo da condição é discutido.
Palavras-chave
Osteonecrose, maxilares, osteoporose
References
1. Neville BW, Damm DD, Allen CM, Bouquot JE. Patologia oral e maxilofacial. 3ª ed. Rio de Janeiro: Elsevier; 2009.
2. American Association of Oral and Maxillofacial Surgeons. Position paper on bisphosphonates-related osteonecrosis of the jaws. Austr Endod J. 2009; 35: 119-30. PMid:19961450
3. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003; 61:1115-7. http://dx.doi.org/10.1016/S0278-2391(03)00720-1
4. Ruggiero SI, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004; 62:527-34. PMid:15122554. http://dx.doi.org/10.1016/j.joms.2004.02.004
5. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005; 63:1567-75. PMid:16243172. http://dx.doi.org/10.1016/j. joms.2005.07.010
6. Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther. 2007; 29:1548‑58. PMid:17919538. http://dx.doi.org/10.1016/j.clinthera.2007.08.008
7. Favus MJ. Diabetes and the risk of osteonecrosis of the jaw [editorial]. J Clin Endocrinol Metab. 2007; 92):817-8.
8. Cheng A, Mavrakokki A, Carter G, Stein B, Fazzalari NL, Wilson DF, et al. The dental implications of bisphosphonates and bone disease. Australian Dental Journal Medications Supplement. 2005; 50 (4):4-13.
9. Gutta R, Louis PJ. Bisphosphonates and osteonecrosis of the jaws: science and rationale. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007; 104:183-96. PMid:17448709. http://dx.doi.org/10.1016/j.tripleo.2006.12.004
10. Bilezikian JP. Osteonecrosis of the jaw. Do bisphosphonates pose a risk? N Engl J Med. 2006; 355:2278–81. PMid:17135582. http://dx.doi. org/10.1056/NEJMp068157
11. Woo SB, Hellstein JW, Kalmar JR. Bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006; 144:753-6. [Erratum, Ann Intern Med 2006;145:235.]. PMid:16702591
12. Filleul O, Crompot E, Saussez S. Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases. J Cancer Res Clin Oncol. 2010; 136:1117–24. PMid:20508948. http://dx.doi.org/10.1007/s00432-010-0907-7
13. Guttemberg AS. Bisphosphonates and bone: what have we learned? Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008; 16:769-72. PMid:18835534. http://dx.doi.org/10.1016/j.tripleo.2008.09.001
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email